Clinical trialNCT05216016CompletedInterventional

Minnesota RETAIN Phase 2 (Sub-study)

SponsorMayo ClinicEnrollment3,414DisabilityIllness Related WorkInjuries Related Work

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

MN RETAIN Phase 2 Sub-study is a non-randomized trial to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Labor (US DOL) and sponsored jointly with the US Social Security Administration. There will be collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay-at-work and return-to-work. MN RETAIN involves a partnership between Mayo Clinic and MN Department of Employment and Economic Development (DEED), MN Department of Labor and Industry (DLI), MN Department of Health (MDH), Workforce Development, Inc. (WDI), and the Governor's Workforce Development Board. MN DEED serves as the main recipient and administrator of the funding within the state with Mayo Clinic, DLI, and WDI, as subrecipients of the grant. (Effective Date: 12/23/2021-05/16/2024) MN RETAIN Phase 2 : This study is a randomized control trial (RCT) to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN. The program is funded by US Department of Labor (US DOL) and sponsored jointly with the US Social Security Administration. There will be collaboration between partners to implement best practices in early intervention to support injured or ill employees in stay-at-work and return-to-work. MN RETAIN involves a partnership between Mayo Clinic and MN Department of Employment and Economic Development (DEED), MN Department of Labor and Industry (DLI), MN Department of Health (MDH), Workforce Development, Inc. (WDI), and the Governor's Workforce Development Board. MN DEED serves as the main recipient and administrator of the funding within the state with Mayo Clinic, DLI, and WDI, as subrecipients of the grant. During this Phase: additional collaborators: Mathematica Policy Research

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Clayton Cowl, MD,MS
Mayo Clinic
Principal Investigator
clinicaltrials.gov ↗
Laura Breeher, MD, MPH
Mayo Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Mayo Clinic Rochester
Rochester, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Dec 2021
Primary completion: 16 May 2026
Completion: 16 May 2026
Last update posted: 27 May 2026
Registered enrollment: 3,414
Registry id: NCT05216016

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.